Journal of Leukemia

Journal of Leukemia
Open Access

ISSN: 2329-6917

+44 1202068036

Citations Report

Citations Report - Journal of Leukemia [386 Articles]

The articles published in Journal of Leukemia have been cited 386 times by eminent researchers all around the world. Following is the list of articles that have cited the articles published in Journal of Leukemia.

Kamini J. Why Imatinib is by Far the Best Drug to Treat Chronic Myeloid Leukemia. Biochem Mol Biol Lett. 2017;3(2):112.

Dhama N, Babu A, Sharma N. Research & Reviews: Journal of Medical and Health Sciences.

GV RR. Types of Cancer and Surgery in Rats (Rattus norvegicus). growth.;91:95.

Ríos-Tamayo R, Pérez MJ, Rodríguez DS, Chang-Chan YL. Epidemiology of Multiple Myeloma. InMultiple Myeloma 2018 Nov 5. IntechOpen.

Walker I, Coady A, Neat M, Ladon D, Benjamin R, El-Najjar I, Kazmi M, Schey S, Streetly M. Is the revised International staging system for myeloma valid in a real world population?. British journal of haematology. 2018 Feb;180(3):451.

Ríos‐Tamayo R, Sáinz J, Martínez‐López J, Puerta JM, Chang DY, Rodríguez T, Garrido P, de Veas JL, Romero A, Moratalla L, López‐Fernández E. Early mortality in multiple myeloma: the time‐dependent impact of comorbidity: A population‐based study in 621 real‐life patients. American journal of hematology. 2016 Jul;91(7):700-4.

Kamini J. Why Imatinib is by Far the Best Drug to Treat Chronic Myeloid Leukemia. Biochem Mol Biol Lett. 2017;3(2):112.

Zahran AM, Saleh M, Mostafa F, Sayed MM, Rayan A, Ali AM, Hetta HF. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. Cancer Biomarkers. 2018 Jan 1;22(3):587-95.

Kamini J. Why Imatinib is by Far the Best Drug to Treat Chronic Myeloid Leukemia. Biochem Mol Biol Lett. 2017;3(2):112.

Ríos-Tamayo R, Pérez MJ, Rodríguez DS, Chang-Chan YL. Epidemiology of Multiple Myeloma. InMultiple Myeloma 2018 Nov 5. IntechOpen.

Cordeiro Santanach A. ARNs no codificants petits en Limfoma de Hodgkin: regulació epigenètica de micro RNAs i importància de la via PIWI/piRNA (Doctoral dissertation, Universitat de Barcelona).

IZHAR NN, MOHAMMAD M, RAHMAN RA, ZAINUDDIN N. MICRORNA AS A POTENTIAL BIOMARKER IN THE DIAGNOSIS AND PROGNOSIS OF HODGKIN’S LYMPHOMA: A SYSTEMATIC REVIEW. INTERNATIONAL JOURNAL OF ALLIED HEALTH SCIENCES. 2019 Aug 8;3(2):694-724.

Szymczyk A, Macheta A, Podhorecka M. Abnormal microRNA expression in the course of hematological malignancies. Cancer Management and Research. 2018;10:4267.

Lopes CB, Magalhães LL, Teófilo CR, Alves AP, Montenegro RC, Negrini M, Ribeiro-dos-Santos Â. Differential expression of hsa-miR-221, hsa-miR-21, hsa-miR-135b, and hsa-miR-29c suggests a field effect in oral cancer. BMC cancer. 2018 Dec;18(1):721.

Cordeiro A, Monzó M, Navarro A. Non-coding RNAs in Hodgkin lymphoma. International journal of molecular sciences. 2017 Jun;18(6):1154.

Zakharova E, Stolyarevich E, Nikitin E. Mantle Cell Lymphoma Associated with Membranoproliferative and Membranous Glomerulonephritis: Report of Two Cases. Cancer Sci Res Open Access. 2016;3(1):1-7.

Oakley PA, Ehsani NN, Harrison DE. The Scoliosis Quandary: Are Radiation Exposures From Repeated X-Rays Harmful?. Dose-Response. 2019 Jun 10;17(2):1559325819852810.

Sanders CL. Radiological Weapons. InRadiobiology and Radiation Hormesis 2017 (pp. 13-44). Springer, Cham.

Pal P. Research & Reviews: Journal of Hospital and Clinical Pharmacy.

Cuttler JM, Mortazavi SJ, Welsh JS, Doss M. Thyroid Cancer Following Childhood Low Dose Radiation Exposure: Fallacies in a Pooled Analysis. J Am Phys Surg. 2017 Dec 22;22:111-2.

Relevant Topics

Top